A two-year Japanese real-world study reports sustained high clearance rates across genital, scalp, and nail psoriasis for bimekizumab, a dual IL-17A/IL-17F inhibitor. The report describes treatment continuity through 104 weeks in 66 patients, supporting durability signals outside controlled clinical settings. The update matters for clinicians managing long-term disease control, especially for multi-site psoriasis where persistence and treatment switching are common. Real-world durability data also informs payer and provider expectations for sustained endpoints. The report frames sustained clearance as the core outcome, rather than new mechanistic findings, aligning with the need for evidence of long-term effectiveness in everyday practice. It adds to a growing evidence set that anti-IL-17 strategies can offer sustained improvements across subtypes when administered continuously.